Author Contributions Conceived and designed the experiments: RER SM ERA JRN. Performed the experiments: RER MG MAG ERA SBA NML. Analyzed the data: References 1. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, et al. (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446: 758–764. 2. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274. 3. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893–898. 4. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108–1113. 5. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, et al. (1985) The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533–538. 6. Verbeek S, van Lohuizen M, van der Valk M, Domen J, Kraal G, et al. (1991) Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol Cell Biol 11: 1176–1179. 7. Cory S, Vaux DL, Strasser A, Harris AW, Adams JM (1999) Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res 59: 1685s–1692s. 8. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL (1999) Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphoma- genesis. Genes Dev 13: 2658–2669. 9. Dyson N (1998) The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245–2262. 10. Attwooll C, Denchi EL, Helin K (2004) The E2F family: specific functions and overlapping interests. EMBO J 23: 4709–4716. 11. Nevins JR (2001) The Rb/E2F pathway and cancer. Hum Mol Genet 10: 699–703. 12. Bates S, Phillips AC, Clark PA, Stott F, Peters G, et al. (1998) p14ARF links the tumour suppressors RB and p53. Nature 395: 124–125. 13. Kowalik TF, DeGregori J, Leone G, Nevins JR (1998) E2F1-specific induction of apoptosis and p53 accumulation is modulated by mdm2. Cell Growth Differ 9: 113–118. 14. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, et al. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424–2433. 15. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR (1997) Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387: 422–426. 16. Sears R, Ohtani K, Nevins JR (1997) Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol Cell Biol 17: 5227–5235. 17. Berns K, Martins C, Dannenberg JH, Berns A, te Riele H, et al. (2000) p27kip1- independent cell cycle regulation by MYC. Oncogene 19: 4822–4827. 18. Leone G, Sears R, Huang E, Rempel R, Nuckolls F, et al. (2001) Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell 8: 105–113. 19. Rempel RE, Saenz-Robles MT, Storms R, Morham S, Ishida S, et al. (2000) Loss of E2F4 activity leads to abnormal development of multiple cellular lineages. Mol Cell 6: 293–306. 20. Lindeman GJ, Dagnino L, Gaubatz S, Xu Y, Bronson RT, et al. (1998) A specific, nonproliferative role for E2F-5 in choroid plexus function revealed by gene targeting. Genes Dev 12: 1092–1098. 21. Dagnino L, Fry CJ, Bartley SM, Farnham P, Gallie BL, et al. (1997) Expression patterns of the E2F family of transcription factors during murine epithelial development. Cell Growth Differ 8: 553–563. 22. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, et al. (1988) The Em-myc transgenic mouse. A model for high incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 167: 353–371. 23. Baudino TA, Maclean KH, Brennan J, Parganas E, Yang C, et al. (2003) Myc- mediated proliferation and lymphomagenesis, but not apoptosis, are compro- mised by E2f1 loss. Mol Cell 11: 905–914. 24. Langdon WY, Harris AW, Cory S, Adams JM (1986) The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 47: 11–18. 25. Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, et al. (2007) Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proc Natl Acad Sci U S A 104: 15400–15405. 26. Sidman CL, Marshall JD, Harris AW (1988) Genetic studies on Em-myc transgenic mice. Curr Top Microbiol Immunol 141: 94–99. 27. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, et al. (1996) Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85: 537–548. 28. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG Jr, et al. (1996) E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85: 549–561. 29. Iritani BM, Eisenman RN (1999) c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci U S A 96: 13180–13185. E2F and Myc-Induced Lymphoma RER SM MG MAG ERA ASL RS CS JRN. Contributed reagents/ materials/analysis tools: SM RS CS. Wrote the paper: RER SM CS JRN. 30. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, et al. (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119–128. 31. Askew DS, Ashmun RA, Simmons BC, Cleveland JL (1991) Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6: 1915–1922. 32. Egle A, Harris AW, Bouillet P, Cory S (2004) Bim is a suppressor of Myc- induced mouse B cell leukemia. Proc Natl Acad Sci U S A 101: 6164–6169. 33. Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL (2001) Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol 21: 7653–7662. 34. Kelly PN, Puthalakath H, Adams JM, Strasser A (2007) Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma. Blood 109: 4907–4913. 35. Lindeman GJ, Adams JM, Cory S, Harris AW (1994) B-lymphoid to granulocytic switch during hematopoiesis in a transgenic mouse strain. Immunity 1: 517–527. 36. Wen R, Chen Y, Bai L, Fu G, Schuman J, et al. (2006) Essential role of phospholipase C gamma 2 in early B-cell development and Myc-mediated lymphomagenesis. Mol Cell Biol 26: 9364–9376. 37. Sidman CL, Denial TM, Marshall JD, Roths JB (1993) Multiple mechanisms of tumorigenesis in E m-myc transgenic mice. Cancer Res 53: 1665–1669. 38. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, et al. (2005) Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436: 787–789. 39. Smith DP, Bath ML, Harris AW, Cory S (2005) T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC. Oncogene 24: 3544–3553. 40. Enos ME, Bancos SA, Bushnell T, Crispe IN (2008) E2F4 modulates differentiation and gene expression in hematopoietic progenitor cells during commitment to the lymphoid lineage. J Immunol 180: 3699–3707. 41. Mori S, Rempel RE, Chang JT, Yao G, Lagoo AS, et al. (2008) Utilization of pathway signatures to reveal distinct types of B lymphoma in the Em-myc model and human DLBCL. Cancer Res 68: 8525–8534. 42. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, et al. (1998) The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17: 5001–5014. 43. Raghunandan R, Ruiz-Hidalgo M, Jia Y, Ettinger R, Rudikoff E, et al. (2008) Dlk1 influences differentiation and function of B lymphocytes. Stem Cells Dev 17: 495–507. 44. Sakajiri S, O’Kelly J, Yin D, Miller CW, Hofmann WK, et al. (2005) Dlk1 in normal and abnormal hematopoiesis. Leukemia 19: 1404–1410. 45. Katoh M (2007) Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev 3: 30–38. 46. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, et al. (2006) Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 354: 2431–2442. 47. Humbert PO, Rogers C, Ganiatsas S, Landsberg RL, Trimarchi JM, et al. (2000) E2F4 is essential for normal erythrocyte maturation and neonatal viability. Mol Cell 6: 281–291. 48. Danielian PS, Bender Kim CF, Caron AM, Vasile E, Bronson RT, et al. (2007) E2F4 is required for normal development of the airway epithelium. Dev Biol 305: 564–576. 49. Kinross KM, Clark AJ, Iazzolino RM, Humbert PO (2006) E2f4 regulates fetal erythropoiesis through the promotion of cellular proliferation. Blood 108: 886–895. 50. Li FX, Zhu JW, Hogan CJ, DeGregori J (2003) Defective gene expression, S phase progression, and maturation during hematopoiesis in E2F1/E2F2 mutant mice. Mol Cell Biol 23: 3607–3622. 51. Zhu JW, Field SJ, Gore L, Thompson M, Yang H, et al. (2001) E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis. Mol Cell Biol 21: 8547–8564. 52. Murga M, Fernandez-Capetillo O, Field SJ, Moreno B, Borlado LR, et al. (2001) Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity 15: 959–970. 53. Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, et al. (2001) The E2F1-3 transcription factors are essential for cellular proliferation. Nature 414: 457–462. 54. Leone G, DeGregori J, Yan Z, Jakoi L, Ishida S, et al. (1998) E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev 12: 2120–2130. 55. Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118–127. 56. Bild A, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353–357. PLoS Genetics | www.plosgenetics.org 15 September 2009 | Volume 5 | Issue 9 | e1000640